KinasePro

Kinase Chemistry – Just a year and a half behind the times.

WO2006127961

Posted by kinasepro on December 1, 2006

Hi Scripps, nice indolinones. I don’t generally hit academic patent apps, but for this one… Well for this one – at least someone out there knows why this is a good one to put up.

…Enhanced and unexpected drug like properties that advantageously distinguishes this class of compounds over the known… yada yada yada

alpha-OH > beta-OH

got amid?

To get a patent app. like this accepted where you’re basically saying: yah we know we’re super close to other known stuff, but this stuff is better because of X. You generally have to provide details about X, in this case which of those drug like properties were improved? While I didn’t go over this one with a fine-toothed comb, I didn’t see any PK, CYP, or even solubility data published 😦

More plz

Advertisements

3 Responses to “WO2006127961”

  1. I guess the freedom to operate argument doesn’t matter with these compounds anymore, with Pfizer (aka Sugen, whose patent these are probably closest to?) having just done a deal with Scripps to commercialise their research

    http://www.sun-sentinel.com/news/local/palmbeach/sfl-pzscripps01dec01,0,5950303.story?coll=sfla-news-palm

  2. milkshake said

    “Propositions under 7: What we cannot speak about we must pass over in silence”

  3. kinasepro said

    Scripps will receive $20 million a year in unrestricted payments.

    Nice.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: